mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Live updates

1. 14h ago

   Moderna and Merck's mRNA Cancer Vaccine Succeeds in Phase 3 Melanoma Trial

   Moderna and Merck's personalized mRNA cancer vaccine, used alongside KEYTRUDA, has shown statistically significant and clinically meaningful results in a Phase 3 trial for adjuvant melanoma, improving recurrence-free survival and distant metastasis-free survival. The vaccine targets specific tumor mutations using AI and T-cell priming. This marks a significant milestone for mRNA technology in oncology.

   Why it matters

   The success of this vaccine is crucial as it transitions mRNA technology from infectious disease applications to oncology. Melanoma is one of the most aggressive forms of skin cancer, and current treatments have limitations. The collaboration between Moderna and Merck demonstrates the potential for personalized cancer vaccines.

   What is confirmed

   • Moderna and Merck's mRNA cancer vaccine improved recurrence-free survival and distant metastasis-free survival in a Phase 3 trial for adjuvant melanoma.
   • The vaccine targets 34 cancer neoantigens and is used in combination with KEYTRUDA.
   • Around 1,089 patients with high-risk, stage IIB-IV melanoma participated in the V940-001 trial.
   • The primary endpoint of the trial is recurrence-free survival, with overall survival and metastasis-free survival as secondary endpoints.
   • Five-year results showed a 49% reduction in disease progression or death.

   Still unconfirmed

   • Results for the V940-001 trial are estimated to be available sometime from 2029.

   What to watch next

   • Phase 3 trial results for V940-001
   • Potential FDA approval and commercialization of the vaccine
   • Expansion of the vaccine's use to other types of cancer
   Sources used for this update (8)

   1. pharmaphorum.com — MSD, Moderna start phase 3 trial of mRNA cancer jab
   2. pharmaphorum.com — Data builds behind Moderna's skin cancer vaccine
   3. lacrossetribune.com — Inside Moderna and Merck's cancer vaccine breakthrough
   4. marketchameleon.com — Moderna’s individualized mRNA cancer therapy hits a Phase 3...
   5. cepa.org — Forging a Transatlantic Biotechnology Partnership to Confront the China Challenge - CEPA
   6. finance.yahoo.com — Moderna stock hits 4-year high on planned national cancer vaccine effort
   7. phillyfightscancer.org — A New mRNA Vaccine Could Help Prevent Skin Cancer from ...
   8. globalhealthcaremagazine.com — Tempus Moderna & Merck Collaboration For Cancer Care Expands
   confidence 85%
2. 4d ago

   Moderna and Merck mRNA Vaccine Meets Phase 3 Melanoma Endpoints

   Intismeran autogene improved recurrence-free survival and distant metastasis-free survival in a Phase 3 trial for adjuvant melanoma. The personalized vaccine combines AI and T-cell priming to target specific tumor mutations. When used alongside KEYTRUDA, the treatment showed statistically significant and clinically meaningful results compared to using the immunotherapy alone. This success marks a transition for mRNA technology from infectious disease applications to oncology, though researchers acknowledge that many questions about cancer vaccines remain unanswered.

   Why it matters

   The COVID-19 pandemic validated mRNA as a therapeutic platform. This success accelerated the development of oncology applications, which now include a wide array of candidates targeting non-communicable diseases.

   What is confirmed

   • Intismeran autogene met its primary endpoint in a Phase 3 trial for adjuvant melanoma.
   • The vaccine showed statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone.
   • The treatment utilizes AI and T-cell priming to target individual tumor mutations.

   Still unconfirmed

   • A 2026 analysis identified 244 vaccine and therapeutic candidates, with 102 focusing on cancer.
   • Of the 244 candidates, 227 are in early clinical development and 12 are in late-stage development.
   • 85 developers, including 50 companies and 35 institutes and hospitals, are working in the mRNA vaccine space.

   What to watch next

   • Regulatory filing and approval decisions for intismeran autogene
   • Clinical trial results for the other 11 late-stage mRNA candidates
   Sources used for this update (3)

   1. www.biospectrumasia.com — mRNA’s Cancer BreakthroughmRNA’s Cancer Breakthrough
   2. www.statnews.com — Divergent trial results on cancer vaccines have field grappling with hard questions
   3. guavy.com — mRNA Cancer Vaccine Shows Promise in Melanoma Trial
   confidence 90%
3. 6d ago

   Moderna and Merck's mRNA cancer vaccine succeeds in Phase 3 melanoma trial

   Moderna and Merck's investigational personalized cancer vaccine, intismeran autogene, met its primary endpoint in a Phase 3 trial for adjuvant melanoma. The treatment uses AI and T-cell priming to target individual tumor mutations. The vaccine, designed to train and activate the immune system to recognize and fight cancer, showed statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone.

   Why it matters

   This development is significant as it marks a potential breakthrough in cancer treatment, offering a new approach to fighting melanoma. The success of this vaccine could pave the way for its application in other tumor types. The companies plan to present data at an upcoming international medical meeting and engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA.

   What is confirmed

   • Moderna and Merck's Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its primary endpoint in melanoma.
   • The combination regimen demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival.
   • Intismeran autogene is an mRNA-based individualized neoantigen therapy designed specifically for each patient based on the unique set of mutations within their tumor.

   What to watch next

   • Data presentation at an upcoming international medical meeting
   • Regulatory submissions for intismeran autogene in combination with KEYTRUDA
   • Commercialization and potential application in other tumor types
   Sources used for this update (13)

   1. www.elle.com — What to Know About the New Cancer Vaccine
   2. www.merck.com — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoin....
   3. finance.yahoo.com — Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo...
   4. finance.yahoo.com — Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success ...
   5. www.medscape.com — Personalized Cancer Vaccines: What Challenges Remain? - Medscape
   6. www.theweek.in — How personalised mRNA vaccines are fighting melanoma
   7. cde.news — Moderna, Merck breakthrough could usher in wave of cancer ...
   8. stocktwits.com — META Stock Rides Muse AI To Best Quarter In Over 2 Years — But Analyst Warns Monetization Could Be 'Not....
   9. en.wikipedia.org — Messenger RNA - Wikipedia
   10. en.wikipedia.org — mRNA vaccine - Wikipedia
   11. my.clevelandclinic.org — mRNA Vaccines: What They Are & How They Work - Cleveland Clinic
   12. www.genome.gov — Messenger RNA (mRNA)
   confidence 100%
4. 23d ago

   Moderna and Merck Phase 3 Melanoma Vaccine Meets Primary Endpoint

   Moderna and Merck have confirmed that their investigational personalized cancer vaccine, intismeran autogene, met its primary endpoint in a Phase 3 trial for adjuvant melanoma. The treatment utilizes AI and T-cell priming to target individual tumor mutations. President Stephen Hoge stated that these positive results support a larger strategic push to apply T-cell priming across various other tumor types. While the clinical trial succeeded, analysts suggest the primary remaining challenge for the therapy is commercialization.

   Why it matters

   The vaccine is used in combination with pembrolizumab to reduce the risk of cancer recurrence. This approach represents a shift toward personalized medicine where vaccines are tailored to a patient's specific genetic mutations. Success in this trial places Moderna and Merck ahead of five other competitors in the personalized therapy market.

   What is confirmed

   • The Phase 3 melanoma trial of intismeran autogene met its primary endpoint.
   • Moderna President Stephen Hoge said the results support using T-cell priming in multiple tumor types.

   What to watch next

   • FDA approval decision for intismeran autogene
   • Commercial launch strategy and pricing
   • Trial results for other tumor types using T-cell priming
   Sources used for this update (2)

   1. finance.yahoo.com — Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
   2. www.pymnts.com — Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merck
   confidence 100%
5. 26d ago

   Merck and Moderna Lead Personalized Cancer Vaccine Field After Melanoma Trial Win

   Moderna and Merck have established a lead in the personalized cancer vaccine market following a successful Phase 3 trial for melanoma. Their treatment, which pairs a tailored mRNA vaccine with pembrolizumab, significantly lowers the risk of melanoma recurrence by targeting individual tumor mutations. This result has positioned the two companies ahead of at least five other drugmakers currently developing similar personalized therapies. The success creates a path for potential FDA approval and shifts the standard for skin cancer treatment.

   Why it matters

   Traditional cancer treatments often use a one-size-fits-all approach. These personalized vaccines are engineered to match the specific genetic profile of a patient's tumor. This shift toward precision medicine aims to increase efficacy and reduce recurrence rates.

   What is confirmed

   • Moderna and Merck's personalized mRNA cancer vaccine paired with pembrolizumab reduced melanoma recurrence in a Phase 3 trial.
   • The treatment is customized to target individual tumor mutations.

   What to watch next

   • FDA approval decision for the mRNA melanoma vaccine
   • Clinical trial results from the five competing drugmakers
   Sources used for this update (4)

   1. arstechnica.com — Beth Mole
   2. www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
   3. finance.biggo.com — Ethan Weiss: Two Trial Flops End the "Genetics Is Undefeated" Era in Heart Drugs
   4. www.biospace.com — 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
   confidence 90%
6. 40d ago

   Moderna and Merck's mRNA cancer vaccine succeeds in Phase 3 melanoma trial

   Moderna and Merck's personalized mRNA cancer vaccine, paired with pembrolizumab, significantly reduced the risk of melanoma recurrence in a Phase 3 trial. The treatment is tailored to individual tumor mutations. This success paves the way for potential FDA approval and a new approach to skin cancer treatment.

   Why it matters

   The vaccine marks a shift from one-size-fits-all approaches in cancer treatment. Melanoma patients may benefit from a more targeted therapy. The trial results offer hope for treating people with cancer. More research is needed to get effective vaccines to the clinic.

   What is confirmed

   • Moderna and Merck's personalized mRNA cancer vaccine, paired with pembrolizumab, significantly reduced the risk of melanoma recurrence in a Phase 3 trial.
   • The treatment is tailored to individual tumor mutations.
   • The therapy was tested in combination with Merck's pembrolizumab.

   What to watch next

   • FDA approval process for the mRNA cancer vaccine
   • Further research on the vaccine's effectiveness in treating other types of cancer
   • Potential partnership or collaboration between Moderna and Merck for future developments
   Sources used for this update (4)

   1. san.com — A cancer vaccine breakthrough, medical AI faces a reality check and recalls pile up
   2. www.nature.com — The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
   3. jen.jiji.com — Ranucci, Milena Gabanelli: "Change in leadership? Long live Report"
   4. finance.yahoo.com — Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy
   confidence 90%
7. 45d ago

   Moderna's mRNA cancer vaccine succeeds in Phase 3 melanoma trial

   Moderna and Merck's personalized mRNA cancer vaccine, paired with pembrolizumab, significantly reduced the risk of melanoma recurrence in a Phase 3 trial. The treatment is tailored to individual tumor mutations, marking a shift from one-size-fits-all approaches. The vaccine helped melanoma patients stay cancer-free longer. This success paves the way for potential FDA approval and a new approach to skin cancer treatment.

   Why it matters

   Melanoma is a serious form of skin cancer with high recurrence rates. Current treatments often have varying degrees of success. The partnership between Moderna and Merck combines cutting-edge mRNA technology with immunotherapy, offering hope for more effective and personalized treatments. The positive Phase 3 trial results are a crucial step toward bringing this innovative treatment to market.

   What is confirmed

   • The personalized mRNA vaccine, paired with pembrolizumab, reduced the risk of melanoma recurrence in a Phase 3 trial.
   • The treatment combines a neoantigen mRNA vaccine with the immunotherapy drug pembrolizumab.
   • The successful trial represents the final clinical step required before seeking FDA approval.

   What to watch next

   • FDA approval process for the mRNA cancer vaccine
   • Potential market launch and availability of the treatment
   • Further research on the vaccine's effectiveness in other types of cancer
   Sources used for this update (5)

   1. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
   2. en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
   3. www.sciencenews.org — A new cancer vaccine may keep melanoma from coming back
   4. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
   5. www.wbur.org — What does Moderna's melanoma treatment mean for cancer research? We asked 2 local experts
   confidence 100%
8. 49d ago

   Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence in Phase 3 Trial

   Moderna and Merck announced that their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning during a phase 3 clinical trial. The treatment combines a neoantigen mRNA vaccine with the immunotherapy drug pembrolizumab. This successful trial represents the final clinical step required before the companies can seek FDA approval. The results suggest a shift toward treatments tailored to the specific mutations of individual tumors rather than a one-size-fits-all approach to skin cancer.

   Why it matters

   Melanoma is a highly aggressive skin cancer prone to relapse. This trial tests whether mRNA technology, used previously for infectious diseases, can train the immune system to recognize and attack tumor-specific proteins.

   What is confirmed

   • Moderna and Merck developed a personalized mRNA cancer vaccine that reduces melanoma recurrence.
   • The treatment combines an mRNA vaccine with the immunotherapy drug pembrolizumab.
   • The vaccine successfully completed phase 3 clinical trials.

   What to watch next

   • FDA approval decision for the mRNA vaccine
   • Data on long-term survival rates for trial participants
   Sources used for this update (4)

   1. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
   2. www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
   3. www.medicalnewstoday.com — Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
   4. moneymorning.com — Moderna's Cancer Vaccine Just Cleared a Real Phase 3 Bar
   confidence 100%
9. 51d ago

   Moderna and Merck's mRNA Cancer Vaccine Succeeds in Phase 3 Melanoma Trial

   Moderna and Merck's mRNA cancer vaccine showed promise in a late-stage trial, preventing melanoma from returning. The vaccine, which uses Moderna's mRNA technology, achieved its primary goal in the Phase 3 trial. This development has significant implications for the treatment of melanoma and the use of mRNA technology in cancer therapy.

   Why it matters

   Melanoma is a serious form of skin cancer that can be fatal if not treated promptly. Current treatments for melanoma include surgery, chemotherapy, and immunotherapy. The success of Moderna and Merck's mRNA cancer vaccine in a Phase 3 trial marks a significant advancement in the field of cancer therapy. mRNA technology has shown promise in the development of vaccines and treatments for various diseases, including cancer.

   What is confirmed

   • Moderna's stock surged 90% following the announcement of the positive Phase 3 trial results.
   • The mRNA cancer vaccine showed promise in preventing melanoma from returning in patients.
   • Moderna and Merck collaborated on the development of the mRNA cancer vaccine.

   What to watch next

   • Future regulatory approvals and commercialization of the mRNA cancer vaccine
   • Additional trial results and long-term efficacy data
   • Potential applications of mRNA technology in other cancer treatments
   Sources used for this update (5)

   1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
   2. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
   3. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
   4. Ars Technica — mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
   5. Yahoo Finance — Moderna stock surges as melanoma vaccine trial shows "landmark moment"
   confidence 92%